Drug intelligence / Profile preview

RG7160 + cisplatin + pemetrexed

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of RG7160 (GA201/imgatuzumab), cisplatin, and pemetrexed. RG7160 is a humanized and glycoengineered immunoglobulin G1 anti-EGFR monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). This combination has been investigated for the treatment of non-squamous non-small cell lung cancer (NSCLC).

Other names: GA201 + cisplatin + pemetrexedimgatuzumab + cisplatin + pemetrexed

Targets

FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on RG7160 + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG7160 + cisplatin + pemetrexed.

Explore the full profile